Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256382 | 0.82 | NPC1 (0.55) | CHEK2FLT1CLK1KMT2AKDM4E | |
| SCHEMBL24256376 | 0.81 | CHEK2 (0.48) | CHEK2FLT1CLK1KMT2AKDM4E | |
| SCHEMBL24256613 | 0.79 | RAD52 (0.47) | PDE5AKMT2AKDM4ECHRM4RAD52 | |
| SCHEMBL23378077 | 0.79 | ALDH1A1 (0.54) | KMT2AKDM4ERAB9AMAPTHTT | |
| SCHEMBL13164877 | 0.70 | SMN1; SMN2 (0.59) | PDE5AKMT2AKDM4ERAB9ARAD52 | |
| SCHEMBL24256881 | 0.70 | NPC1 (0.53) | KMT2AKDM4ERAB9ACHRM4MAPT | |
| SCHEMBL26780613 | 0.68 | KDM4E (0.44) | CHEK2FLT1CLK1KDM4ERAB9A | |
| SCHEMBL4898987 | 0.68 | KDM4E (0.64) | CHEK2CLK1KDM4ECLK4MAPT | |
| SCHEMBL26780303 | 0.68 | NPC1 (0.55) | CHEK2FLT1CLK1KMT2AKDM4E | |
| SCHEMBL24256886 | 0.67 | NPC1 (0.50) | KMT2AKDM4ERAB9ACHRM4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022035806-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | PDE5A 2849/4885CHEK2 1346/4885FLT1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.